US health care giant Johnson & Johnson subsidiary Janssen-Cilag International has submitted a Marketing Authorization Application to the European Medicines Agency for ibrutinib for the treatment of adult patients with two forms of blood cancer. 31 October 2013
Swedish specialty pharma group Pharmalink says its product Busulipo, (busulfan), a best-in-class conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation has received Orphan Drug designation from the US Food and Drug Administration. 29 October 2013
US drug major Bristol-Myers Squibb and partner privately-held Alder Biopharmaceuticals have presented efficacy and safety data from a Phase IIb dose-ranging study of subcutaneous clazakizumab in adults with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to methotrexate). 29 October 2013
Data from two pivotal large-scale Phase III registration studies with German independent drug major Boehringer Ingelheim’s afatinib, LUX-Lung 3 and LUX-Lung 6, showed superior efficacy and a manageable safety profile in both Asian and non-Asian lung cancer patients compared to chemotherapy. 28 October 2013
US biotech company Celgene Corp reported third quarter 2013 total revenue of $1.67 billion compared to $1.42 million in the third quarter 2012, just beating expectations of $1.64 billion. Net product sales came in at $1.64 billion, an 18% increase from the same period in 2012. 25 October 2013
Australian drug development and pharmaceutical company Imugene says it has executed a sale and purchase agreement to acquire 100% of Biolife Science Qld, a company incorporated in Australia. 24 October 2013
Merck Serono and Poland-based biotech firm Selvita have entered into a collaboration to jointly discover small molecule-based drugs targeting proteins involved in cancer cell metabolism. 24 October 2013
The UK drug watchdog the National Institute for Health and Care Excellence (NICE) today issued final draft guidance that does not recommend US biotech firm Celgene’s blockbuster multiple myeloma drug Revlimid (lenalidomide) for treating some myelodysplastic syndromes (MDS). 24 October 2013
AstraZeneca has initiated its Phase III clinical program for selumetinib being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) whose tumors are KRAS mutation-positive. 24 October 2013
Netherlands company Qiagen has announced a partnership with Clovis Oncology to co-develop and co-commercialize a companion diagnostic test to guide the use of CO-1686. 24 October 2013
Medivation and Japanese drug major Astellas Pharma have announced positive results from the Phase III PREVAIL trial of enzalutamide in prostate cancer. 23 October 2013
Angiochem has announced complete results of a Phase II clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in breast cancer patients with brain metastasis. 22 October 2013
US biotech firm Ariad Pharmaceuticals’took another tumble, falling 35% to $2.91, as the company said that it is discontinuing the Phase III EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia. 18 October 2013
The uterine cancer treatments market has been forecast to increase at a compound annual growth rate (CAGR) of 3.9% over the next five years, increasing from a total of $17.8 billion in 2013, to reach a total of $21.6 billion in 2018. 18 October 2013
NICE has issued new draft guidance recommending Xtandi from Astellas Pharma as an option for treating hormone relapsed metastatic prostate cancer in adults. 18 October 2013
Celgene International, a wholly-owned subsidiary of Celgene Corp, has announced the results of the MPACT Phase III clinical trial of Abraxane in combination with gemcitabine. 17 October 2013
Privately-held US biotech firm TARIS Biomedical has entered into a research collaboration with Anglo-Swedish drug major AstraZeneca to evaluate novel treatments for bladder cancer. 17 October 2013
Roche reported that sales for the first nine months of 2013 have increased 6% to 34.9 billion Swiss francs ($38.36 billion), with third-quarter revenues rising a strong 8% to 11.57 billion francs and just beating consensus forecasts of 11,54 billion francs. 17 October 2013
Indian drugmaker Zydus Cadila has entered into an alliance with privately-held German company Pieris AG for development and commercialization of multiple novel Anticalin-based protein therapeutics. 16 October 2013
Merck & Co and partner Endocyte today announced the on-line publication of results from the randomized Phase II PRECEDENT trial for vintafolide, an investigational folate small molecule drug conjugate, demonstrating significant progression free survival in ovarian cancer. 15 October 2013
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024